Am J Pathol

1. HUAI Q, Li X, Wang H, Yin S, et al
   The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease and Associated Hepatocellular Carcinoma: Pathogenesis and Therapeutic Interventions.
   Am J Pathol. 2026 Sep 25:S0002-9440(26)00282.
   

   >> Share

   
   
2. LEE V, Chiang CC, Balogun O, Cornuet P, et al
   Wnt/beta-catenin reduces fibrosis and enhances hepatocyte reprogramming during cholestasis independent of Yap signaling.
   Am J Pathol. 2026 Sep 25:S0002-9440(26)00281.
   

   >> Share

   
   

   
   Biochem Biophys Res Commun

3. NAKATSUKASA Y, Hirano M, Yamada Y, Ohta S, et al
   MYCN reprograms postnatal cells toward embryonic-like transcriptional states and drives tumorigenesis.
   Biochem Biophys Res Commun. 2026;835:154488.
   

   >> Share

   
   

   
   BMC Gastroenterol

4. RAVANSHAD S, Golestani MN, Ahadi M, Kabiri M, et al
   Evaluation of sleep quality and obstructive sleep apnea in non-alcoholic fatty liver disease: a cross-sectional study.
   BMC Gastroenterol. 2026;26:583.
   

   >> Share

   
   

   
   Gastroenterology

5. MCCOY MS, Peiffer KH, Hahner JM, Praktiknjo M, et al
   When the Beat and the Bleed Compete: An Opportunity for INTERBLEED Subgroup Analysis in Patients With Liver Cirrhosis.
   Gastroenterology. 2026 Sep 21:S0016-5085(26)07256.
   

   >> Share

   
   

   
   Gastrointest Endosc

6. MARYA NB, Cosgrove N, Thiruvengadam NR, Nasser-Ghodsi N, et al
   American Society for Gastrointestinal Endoscopy guideline on management of esophageal and gastric varices in patients with cirrhosis.
   Gastrointest Endosc. 2026 Sep 25:S0016-5107(26)06936.
   

   >> Share

   
   

   
   Gut

7. ARMSTRONG MJ, Williams FR
   Rapid skeletal muscle loss in cirrhosis: the 'silent killer' within CT imaging.
   Gut. 2026 Sep 21:gutjnl-2026-340144. doi: 10.1136/gutjnl-2026-340144.
   

   >> Share

   
   
8. NIKITINA D, Suk KT, Torre A, Idilman R, et al
   Hospitalisation in cirrhosis is linked to distinct gut microbiome structural and functional profiles: a multinational metagenomic study.
   Gut. 2026 Sep 21:gutjnl-2026-339378. doi: 10.1136/gutjnl-2026-339378.
   

   >> Share

   
   
9. ZHANG L, Chen C, Xu Y, Zhang Y, et al
   Integrative multi-omics landscape and diagnostic-therapeutic modelling of steatohepatitic hepatocellular carcinoma.
   Gut. 2026 Sep 22:gutjnl-2026-339304. doi: 10.1136/gutjnl-2026-339304.
   

   >> Share

   
   
10. ZHANG J, Zhang M, Juramt D, Qi W, et al
    Single-nucleus transcriptomics refine the hepatic cellular context of the MASLD proteosurvival signature.
    Gut. 2026 Sep 22:gutjnl-2026-340378. doi: 10.1136/gutjnl-2026-340378.
    

    >> Share

    
    
11. TAO L, Liu N, Zhang W, Yang Z, et al
    Butyrylcholinesterase alleviates hepatic stellate cell activation via paracrine muscarinic signalling.
    Gut. 2026 Sep 23:gutjnl-2026-338932. doi: 10.1136/gutjnl-2026-338932.
    

    >> Share

    
    
12. PEISELER M, Bengsch B
    Checkpoints in circulation: extracellular vesicles can predict immunotherapy response and resistance in hepatocellular carcinoma.
    Gut. 2026 Sep 24:gutjnl-2026-340093. doi: 10.1136/gutjnl-2026-340093.
    

    >> Share

    
    
13. YARCHOAN M, Llovet JM, Kelley RK, Finn R, et al
    Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies.
    Gut. 2026 Sep 24:gutjnl-2026-339505. doi: 10.1136/gutjnl-2026-339505.
    

    >> Share

    
    

    
    Hepatology

14. FERNANDEZ-IGLESIAS A, Harris EN, Jalan-Sakrikar N, Kaur S, et al
    The hepatic sinusoid as a regulatory niche: From cellular specialization to precision hepatology.
    Hepatology. 2026 Sep 24. doi: 10.1097/HEP.0000000000001870.
    

    >> Share

    
    
15. KE AW, Shi GM, Zhou J, Wu FZ, et al
    Erratum: Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma.
    Hepatology. 2026 Sep 24. doi: 10.1097/HEP.0000000000001848.
    

    >> Share

    
    

    
    J Clin Oncol

16. PEETERS SLJ, Uluc E, Rousian M, Groot Koerkamp B, et al
    Hepatic Arterial Infusion of Oxaliplatin After Liver Metastases Resection: Interpreting Efficacy and Toxicity.
    J Clin Oncol. 2026 Sep 24:JCO2601218. doi: 10.1200/JCO-26-01218.
    

    >> Share

    
    
17. GELLI M, Tanguy ML, Tselikas L, Malka D, et al
    Reply to: Hepatic Arterial Infusion of Oxaliplatin After Liver Metastases Resection: Interpreting Efficacy and Toxicity.
    J Clin Oncol. 2026 Sep 24:JCO2601748. doi: 10.1200/JCO-26-01748.
    

    >> Share

    
    

    
    J Gastroenterol Hepatol

18. LAU SY, Chan WK
    Letter to Editor-In Response to "The Malaysian Society of Gastroenterology and Hepatology Consensus Statements on Prevention and Early Detection of Hepatocellular Carcinoma in Malaysia".
    J Gastroenterol Hepatol. 2026 Sep 22. doi: 10.1111/jgh.70770.
    

    >> Share

    
    
19. BALOCH MSA, Rehman QSU, Saleem MZ
    Re: The Malaysian Society of Gastroenterology and Hepatology Consensus Statements on Prevention and Early Detection of Hepatocellular Carcinoma in Malaysia.
    J Gastroenterol Hepatol. 2026 Sep 21. doi: 10.1111/jgh.70771.
    

    >> Share

    
    
20. LAU G
    Translational Hepatology From Bedside to Global Policy: How Robust Clinical and Translational Research Reshapes Global Practice Guidelines and Patient Outcomes.
    J Gastroenterol Hepatol. 2026 Sep 21. doi: 10.1111/jgh.70742.
    

    >> Share

    
    

    
    J Hepatol

21. VAN DER MERWE S, Korf H
    When containment fails: beta-adrenergic disruption of the gut-liver barrier in cirrhosis.
    J Hepatol. 2026 Sep 25:S0168-8278(26)02903-X. doi: 10.1016/j.jhep.2026.
    

    >> Share

    
    
22. CHENHAO J, Lu H, Yasong L, Jianhao Z, et al
    Restoration of aged liver regeneration by youthful systemic factors via LTbeta-driven hepatocyte reprogramming.
    J Hepatol. 2026 Sep 22:S0168-8278(26)02893-X. doi: 10.1016/j.jhep.2026.
    

    >> Share

    
    

    
    PLoS One

23. METTANANDA C, Sivasumithran K, Ranaweera L, Madhubhashini A, et al
    Optimisation of metabolic dysfunction-associated steatotic liver disease (MASLD) screening algorithm for resource-poor settings using machine learning.
    PLoS One. 2026;21:e0352231.
    

    >> Share

    
    

    
    Transplantation

24. FANG Y, Bouari S, van de Wetering J, den Hoed CM, et al
    Simultaneous Liver-kidney Versus Liver Transplantation Categorized by Pretransplant eGFR: Impact of the 2017 OPTN Policy.
    Transplantation. 2026 Jun 30. doi: 10.1097/TP.0000000000005776.
    

    >> Share

    
    
25. FOZOUNI L, Cullaro G, Lai JC, Wadhwani SI, et al
    Metabolic Dysfunction-associated Liver Disease Associated With Poor Food Access and Geographic hot Spots Among Liver Transplant Candidates.
    Transplantation. 2026 Jun 25. doi: 10.1097/TP.0000000000005813.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share